RednessNCT07200635
Test Serum Clinical Study
A study testing HA injection and Facial serum application in people with Redness, run by ChinaNorm at 1 site in China.
Trial summary
This 4-week, mono-centric clinical study employed a randomized three-arm design to evaluate the efficacy of a test serum. The study compared three interventions: the test serum used alone, the test serum used in combination with hyaluronic acid (HA) injection, and HA injection alone. Read more about this study
- Who is it for?
- Ages 25 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Redness
- What is being tested?
- HA injection and Facial serum application
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteChina
- Study dates
- 23 Jun 2025to 9 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 40 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Chinese female with 25-40 years old.
- All skin types by subjects' self-perceived.
- Willing to perform HA injection.
- Did not perform any of the beauty procedure projects in the past 6 months.
- Lack of hydration, radiance, brightness, smoothness, firmness and elasticity by self-claimed.
- Presenting with corresponding severity for the attribute evaluated by Dermatologist included:
Show all 17Show fewer
- Radiance, smoothness, elasticity, cheek plumpness and firmness: 3≤grade≤6.
- Global fine lines: 3≤grade.
- Underneath eye wrinkles: 2≤grade≤5.
- Forehead wrinkles: 1<grade≤4.
- Glabella wrinkles: 1<grade.
- All accept not to use any cosmetics, skincare products, beauty equipment, all topical medications and cleansing products on face at visit days.
- Did not participate any clinical test or cosmetic product test on skin within 1 months.
- No disagreement of dermatologist because of other reasons that exclude the participation of the volunteer.
- In general, good health at the time of the study.
- Willing and able to participate as evidenced by signing of informed consent \& photo release form.
- Must be willing to comply with all study protocol requirements.
Who cannot join
- Pregnant or breast-feeding woman or woman planning pregnancy during the study.
- Subject deprived of rights by a court or administrative order.
- Major subject to a guardianship order.
- Subject residing in a health or social care establishment.
- Patient in an emergency setting.
- Subject with a skin disease in the test areas as well as skin allergy (particularly e.g., acne, rosacea, eczema).
Show all 17Show fewer
- Subject presenting a stable or progressive serious disease (per investigator's assessment).
- Immuno-compromised subject.
- Subject with history of allergy to cosmetic or personal care products or ingredients.
- Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).
- Subject with history of sunlight sensitivity or allergies.
- Subject regularly practicing aquatic or nautical sports.
- Subject regularly attending a sauna.
- Subject with physical highly sensitive constitution.
- Subject with cardiovascular or circulatory history.
- Subject with a history of skin cancer or malignant melanoma.
- Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune-suppressants in the last 6 months before study.
Trial locations and contacts
1 site in 1 country.
China1 site
Shanghai China-norm Quality Technical Service Co., Ltd.
Shanghai, Shanghai Municipality, 200072
About this study
Official title: Test Serum 4-Week Clinical Study
This 4-week, mono-centric clinical study employed a randomized three-arm design to evaluate the efficacy of a test serum. The study compared three interventions: the test serum used alone, the test serum used in combination with hyaluronic acid (HA) injection, and HA injection alone. It aimed to assess their effects on skin quality and wrinkles in 90 healthy Chinese female subjects aged 25-40. Evaluations were conducted at multiple timepoints through clinical assessments, instrumental measurements, and image analysis.
- Conditions
- Redness
- Being tested
- HA injection, Facial serum application
- Medical subject headings
- Erythema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HA injectionOther
Using vacuum negative pressure technology, hyaluronic acid and other moisturizing nutrients are directly injected into the deep skin, effectively improving dermal dehydration and dryness from the muscle base, so that the skin can quickly replenish water.
Facial serum applicationOther
Dosage on face: About 0.5g/face for serum.
| Study group | Role | What they receive |
|---|---|---|
| Serum Application Regimen | Other | Not described Receives: Other: Facial serum application |
| Combination Regimen | Other | Not described Receives: Other: HA injection; Other: Facial serum application |
| Injection-Exclusive Regimen | Other | Not described Receives: Other: HA injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Skin Hydration Level via Corneometer CM825
Measured: Measurements are taken at Baseline (T0) , 10 minutes post-application (for Group 1 only), 1 hour post-application (T1h) , Day 1 (T1D) , Day 3 (T3D) , Day 7 (T7D) , Day 14 (T14D) , Day 21 (T21D) , and Day 28 (T28D) .
Skin Barrier Function via Vapometer® (TEWL Measurement)
Measured: Measurements are taken at Baseline (T0) , 10 minutes post-application (for Group 1 only), 1 hour post-application (T1h) , Day 1 (T1D) , Day 3 (T3D) , Day 7 (T7D) , Day 14 (T14D) , Day 21 (T21D) , and Day 28 (T28D) .
Skin Elasticity via Cutometer® Dual MPA 580
Measured: Measurements are taken at Baseline (T0) , 10 minutes post-application (for Group 1 only), 1 hour post-application (T1h) , Day 1 (T1D) , Day 3 (T3D) , Day 7 (T7D) , Day 14 (T14D) , Day 21 (T21D) , and Day 28 (T28D) .
Facial Skin Redness and Wrinkle Mapping via VISIA-7 Imaging
Measured: Images are captured at Baseline (T0) , 10 minutes post-application (for Group 1 only), 1 hour post-application (T1h) , Day 1 (T1D) , Day 3 (T3D) , Day 7 (T7D) , Day 14 (T14D) , Day 21 (T21D) , and Da
3D Topographical Analysis of Wrinkles and Pores via Antera 3D
Measured: Measurements are taken at Baseline (T0) , 10 minutes post-application (for Group 1 only), 1 hour post-application (T1h) , Day 1 (T1D) , Day 3 (T3D) , Day 7 (T7D) , Day 14 (T14D) , Day 21 (T21D) , and Day 28 (T28D) .
Subjective Skin Tolerance and Sensation via Self-Assessment Questionnaire
Measured: Questionnaires are administered at Baseline (T0) , 10 minutes post-application (for Group 1 only), 1 hour post-application (T1h) , Day 1 (T1D) , Day 3 (T3D) , Day 7 (T7D) , Day 14 (T14D) , Day 21 (T21D) ,
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2025
- Study start23 Jun 2025
- Primary completion9 Sep 2025
- Study completion9 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for RednessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- ChinaNorm
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07200635
- Sponsor's protocol ID
- C25005046
- Status last verified
- Nov 2025
- First submitted
- 18 Sep 2025
- Last updated
- 17 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Test Serum 4-Week Clinical Study
- ClinicalTrials.gov ID
- NCT07200635
- Acronym / sponsor ID
- C25005046
- Conditions
- Redness
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- ChinaNormIndustry (pharma, biotech, devices)
- Study start
- 23 Jun 2025 (actual)
- Primary completion
- 9 Sep 2025 (actual)
- Study completion
- 9 Sep 2025 (actual)
- First posted
- 1 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This 4-week, mono-centric clinical study employed a randomized three-arm design to evaluate the efficacy of a test serum. The study compared three interventions: the test serum used alone, the test serum used in combination with hyaluronic acid (HA) injection, and HA injection alone. It aimed to assess their effects on skin quality and wrinkles in 90 healthy Chinese female subjects aged 25-40. Evaluations were conducted at multiple timepoints through clinical assessments, instrumental measurements, and image analysis.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Serum Application Regimen | Other | Other: Facial serum application |
| Combination Regimen | Other | Other: HA injection, Other: Facial serum application |
| Injection-Exclusive Regimen | Other | Other: HA injection |
Who may qualify
- Ages
- 25 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (17 listed)
- Chinese female with 25-40 years old.
- All skin types by subjects' self-perceived.
- Willing to perform HA injection.
- Did not perform any of the beauty procedure projects in the past 6 months.
- Lack of hydration, radiance, brightness, smoothness, firmness and elasticity by self-claimed.
Key exclusion criteria (17 listed)
- Pregnant or breast-feeding woman or woman planning pregnancy during the study.
- Subject deprived of rights by a court or administrative order.
- Major subject to a guardianship order.
- Subject residing in a health or social care establishment.
- Patient in an emergency setting.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HA injectionUsing vacuum negative pressure technology, hyaluronic acid and other moisturizing nutrients are directly injected into the deep skin, effectively improving dermal dehydration and dryness from the muscle base, so that the skin can quickly replenish water. | Other | Combination Regimen, Injection-Exclusive Regimen |
| Facial serum applicationDosage on face: About 0.5g/face for serum. | Other | Combination Regimen, Serum Application Regimen |
Primary outcome
Skin Hydration Level via Corneometer CM825
Time frame: Measurements are taken at Baseline (T0) , 10 minutes post-application (for Group 1 only), 1 hour post-application (T1h) , Day 1 (T1D) , Day 3 (T3D) , Day 7 (T7D) , Day 14 (T14D) , Day 21 (T21D) , and Day 28 (T28D) .
Skin Barrier Function via Vapometer® (TEWL Measurement)
Time frame: Measurements are taken at Baseline (T0) , 10 minutes post-application (for Group 1 only), 1 hour post-application (T1h) , Day 1 (T1D) , Day 3 (T3D) , Day 7 (T7D) , Day 14 (T14D) , Day 21 (T21D) , and Day 28 (T28D) .
Skin Elasticity via Cutometer® Dual MPA 580
Time frame: Measurements are taken at Baseline (T0) , 10 minutes post-application (for Group 1 only), 1 hour post-application (T1h) , Day 1 (T1D) , Day 3 (T3D) , Day 7 (T7D) , Day 14 (T14D) , Day 21 (T21D) , and Day 28 (T28D) .
Facial Skin Redness and Wrinkle Mapping via VISIA-7 Imaging
Time frame: Images are captured at Baseline (T0) , 10 minutes post-application (for Group 1 only), 1 hour post-application (T1h) , Day 1 (T1D) , Day 3 (T3D) , Day 7 (T7D) , Day 14 (T14D) , Day 21 (T21D) , and Da
3D Topographical Analysis of Wrinkles and Pores via Antera 3D
Time frame: Measurements are taken at Baseline (T0) , 10 minutes post-application (for Group 1 only), 1 hour post-application (T1h) , Day 1 (T1D) , Day 3 (T3D) , Day 7 (T7D) , Day 14 (T14D) , Day 21 (T21D) , and Day 28 (T28D) .
Subjective Skin Tolerance and Sensation via Self-Assessment Questionnaire
Time frame: Questionnaires are administered at Baseline (T0) , 10 minutes post-application (for Group 1 only), 1 hour post-application (T1h) , Day 1 (T1D) , Day 3 (T3D) , Day 7 (T7D) , Day 14 (T14D) , Day 21 (T21D) ,
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Nov 2025.
Related trials for Redness
Enrolling by invitationPhase 4
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
Pyruvate Kinase Deficiency, Anemia, Hemolytic
Active, not recruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Not yet recruiting
The Effect of 16-week Dietary Intake of Food Supplements Containing Collagen and MSM on Facial Erythema and Other Skin Parameters
Erythema, Telangiectasis
Not yet recruiting
Suture Choice for Ostomy Creation
Ostomy - Ileostomy or Colostomy, Stoma Complications
Active, not recruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing HA injection and Facial serum application in people with Redness, run by ChinaNorm at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Skin Hydration Level via Corneometer CM825 (time frame: Measurements are taken at Baseline (T0) , 10 minutes post-application (for Group 1 only), 1 hour post-application (T1h) , Day 1 (T1D) , Day 3 (T3D) , Day 7 (T7D) , Day 14 (T14D) , Day 21 (T21D) , and Day 28 (T28D) .). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2025.